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Nitescu N, Grimberg E, Ricksten S-E, Marcussen N,
Nordlinder H, Guron G. Effects of thrombin inhibition with
melagatran on renal hemodynamics and function and liver integrity
during early endotoxemia. Am J Physiol Regul Integr Comp
Physiol 292: R1117–R1124, 2007. First published October 26,
2006; doi:10.1152/ajpregu.00471.2006.—Sepsis is associated with an
activation of the coagulation system and multiorgan failure. The aim
of the study was to examine the effects of selective thrombin inhibi-
tion with melagatran on renal hemodynamics and function, and liver
integrity, during early endotoxemia. Endotoxemia was induced in
thiobutabarbital-anesthetized rats by an intravenous bolus dose of
lipopolysaccharide (LPS; 6 mg/kg). Sham-Saline, LPS-Saline, and
LPS-Melagatran study groups received isotonic saline or melagatran
immediately before (0.75 mol/kg iv) and continuously during (0.75
mol kg1 h1 iv) 4.5 h of endotoxemia. Kidney function, renal
blood flow (RBF), and intrarenal cortical and outer medullary perfu-
sion (OMLDF) measured by laser-Doppler flowmetry were analyzed
throughout. Markers of liver injury and tumor necrosis factor (TNF)-
were measured in plasma after 4.5 h of endotoxemia. In addition, liver
histology and gene expression were examined. Melagatran treatment
prevented the decline in OMLDF observed in the LPS-Saline group
(P  0.05, LPS-Melagatran vs. LPS-Saline). However, melagatran
did not ameliorate reductions in mean arterial pressure, RBF, renal
cortical perfusion, and glomerular filtration rate or attenuate tubular
dysfunctions during endotoxemia. Melagatran reduced the elevated
plasma concentrations of aspartate aminotransferase (34  11%,
P 0.05), alanine aminotransferase (21 7%, P 0.05), bilirubin
(44  9%, P  0.05), and TNF- (32  14%, P  0.05) in
endotoxemia. Melagatran did not diminish histological abnormalities
in the liver or the elevated hepatic gene expression of TNF-,
intercellular adhesion molecule-1, and inducible nitric oxide synthase
in endotoxemic rats. In summary, thrombin inhibition with melagatran
preserved renal OMLDF, attenuated liver dysfunction, and reduced
plasma TNF- levels during early endotoxemia.
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ACUTE RENAL FAILURE OCCURS in 20–50% of critically ill patients
with sepsis and multiple organ dysfunction syndrome and is an
independent risk factor contributing to the high mortality of
50–70% in this patient group (33).
Activated coagulation factors are likely to be important
mediators of sepsis-associated organ injury (30, 33, 40). In
support of this notion, activation of the coagulation system and
increased thrombin generation in sepsis have been associated
with intravascular fibrin formation, leukocyte activation and
adhesion, and platelet aggregation (30, 40). These events may
lead to microvascular injury, endothelial dysfunction, general-
ized microthrombosis formation, and impaired blood flow to
several organ systems, thereby causing multiorgan failure (37,
40). Accordingly, thrombin inhibitors have been shown to
improve microvascular perfusion in striated muscle and the
mesentery during endotoxemia (19, 21), although the results
are not conclusive (20, 39). Furthermore, thrombin inhibition
has demonstrated beneficial effects on liver function and sur-
vival in endotoxemic animals in some (3, 31), but not in all (10,
32), studies. In addition to its roles in the coagulation pathway
and in platelet and leukocyte activation, thrombin has also been
shown to cause renal vasoconstriction (11). This effect seems
to be mediated by activation of protease-activated receptor
(PAR)-1 (5, 11, 36). PARs are a novel class of receptors that
are activated by serine proteases and mediate numerous cellu-
lar actions of thrombin (4).
Melagatran is a selective and powerful inhibitor of thrombin
activity and the conversion of fibrinogen to fibrin (13). More-
over, melagatran inhibits thrombin’s activation of PAR-1 and
PAR-4 (28). Interestingly, thrombin inhibition with melagatran
has been suggested to improve kidney function in endotoxemic
pigs, as indicated by reduced plasma creatinine levels (9).
However, in that study no detailed analyses of renal hemody-
namics and function were carried out. Hence, we hypothesized
that melagatran, by inhibiting microthrombosis formation and
PAR-1-mediated renal vasoconstriction, might improve renal
blood flow (RBF) and glomerular filtration rate (GFR) in
endotoxemia. Thus the aim of the present study was to examine
the effects of thrombin inhibition with melagatran on renal
hemodynamics and function, and liver integrity, in a well-
characterized rat model (25) of endotoxemia with multiple
organ dysfunctions.
MATERIALS AND METHODS
General procedures. Male Sprague-Dawley rats (Harlan, Horst,
The Netherlands) weighing 250 g were used. All experiments were
approved by the regional ethics committee in Go¨teborg. Chemicals
were from Sigma (St. Louis, MO) unless otherwise stated. Melagatran
(a generous gift from AstraZeneca, Mo¨lndal, Sweden) was stored and
prepared as described previously (13).
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Protocol 1: Renal hemodynamics and function. Rats were divided
into three study groups, 1) lipopolysaccharide (LPS)-Saline (n  8),
2) LPS-Melagatran (n 8), and 3) Sham-Saline (n 9), anesthetized
with thiobutabarbital (Inactin, 120 mg/kg ip), placed on a heating
table, and prepared for renal clearance experiments as described
previously (27). An arterial line was connected to a pressure trans-
ducer (Smiths Medical, Kirchseeon, Germany) for monitoring of
mean arterial pressure (MAP) and heart rate (HR) with a data
acquisition program (Biopac MP 150, Biopac Systems, Santa Barbara,
CA). The left kidney was exposed by a flank incision and immobilized
in a plastic cup. The left ureter was catheterized for urine collection
into preweighed vials. Rectal and kidney temperatures were kept at
37°C. A perivascular ultrasonic flow probe (0.7 VB, T206, Transonic
Systems, Ithaca, NY) was placed around the left renal artery for
measurement of RBF. Renal cortical (CLDF) and outer medullary
(OMLDF) perfusion were estimated by laser-Doppler flowmetry
(PF5000, Perimed, Stockholm, Sweden). The laser-Doppler signal
was previously demonstrated to provide a reliable estimate of regional
tissue blood flow in the kidney (34). Renal outer medullary laser-
Doppler flux was measured by a needle probe (411, Perimed) inserted
3.5 mm into the kidney, as described previously (27).
Throughout the experiment, rats received 10 ml kg1 h1 of
isotonic saline. After completion of the surgical preparation, a 40-min
equilibration period was allowed before baseline clearance measure-
ments over two consecutive 30-min periods. Subsequently, endotox-
emia was induced by intravenous administration of LPS (Escherichia
coli 0127:B8) in a bolus dose of 6 mg/kg over 30 min. This dose of
LPS causes acute kidney dysfunction and liver injury in a well-
characterized model of endotoxemia in rats (25). The LPS-Melagatran
group received melagatran immediately before LPS administration
(0.75 mol/kg iv bolus) and throughout the experiment (0.75
mol kg1 h1 iv). On the basis of previous studies (7) and pilot
experiments, this dose was expected to produce a plasma melagatran
concentration of 1 mol/l throughout the study period, a concen-
tration known to prolong thrombin time and activated partial throm-
boplastin time and to exert pronounced antithrombotic effects in vivo
(8). Control rats received equivalent volumes of isotonic saline. Renal
hemodynamics and function were measured continuously for 3 h
during endotoxemia.
In a supplementary group of sham-treated animals (Sham-Melagat-
ran, n  8), we investigated the effects of melagatran on renal
hemodynamics and function according to the protocol described
above. Adjusting for normal GFR, these animals received melagatran
in an intravenous bolus dose of 1.0 mol/kg, followed by 1.0
mol kg1 h1 intravenously throughout.
GFR was determined by measuring renal 51Cr-EDTA clearance
(51Cr-EDTA, Amersham) as described previously (12). Arterial blood
samples (0.3 ml) were replaced by equivalent volumes of 4% bovine
serum albumin in isotonic saline. Urine and plasma samples were
analyzed for sodium, potassium, and radioactivity as described pre-
viously (12). Fractional urinary excretion rates of sodium (FENa, %),
potassium (FEK, %), and water (FEH2O , %) were estimated as the ratio
of their respective clearances to that of 51Cr-EDTA  100. Renal
vascular resistance was calculated as MAP (mmHg)/RBF
[ml min1 g kidney wt1] and filtration fraction (FF) as the ratio
between GFR and RBF. Presented baseline data are average values of
the two clearance periods before LPS administration.
Protocol 2: Liver integrity, blood gases, and plasma analyses.
Separate groups of rats [LPS-Saline (n  12), LPS-Melagatran (n 
12), and Sham-Saline (n  11)] were anesthetized and subjected to
endotoxemia and saline or melagatran treatment, following a protocol
identical to protocol 1 described above. However, animals were not
prepared for analyses of renal hemodynamics or clearance measure-
ments, although MAP and HR were measured throughout. In addition,
the protocol was extended to 4.5 h after start of endotoxin adminis-
tration. After 4.5 h, indexes of liver and pancreas injury were assessed
by measuring plasma levels of aspartate aminotransferase (AST),
alanine aminotransferase (ALT), bilirubin, and pancreas-specific
-amylase. Concurrently, arterial blood gases were taken (ABL 510
blood gas analyzer, Radiometer, Copenhagen, Denmark) and blood
was collected for analyses of plasma concentrations of melagatran,
tumor necrosis factor (TNF)-, and nitrate (NO3) and nitrite (NO2).
Animals were killed, and lungs, kidneys, and liver were excised. Lung
wet-to-dry weight ratio was determined after 12 h at 100°C.
Aminotransaminases were analyzed by an enzymatic method, and
bilirubin and -amylase were measured spectrophotometrically (Mod-
ular, Roche Diagnostics, Mannheim, Germany). TNF- was analyzed
with an enzyme-linked immunosorbent assay (ELISA) kit (Rat TNF
ELISA Kit II, BD Biosciences), and NO3/NO2 was measured spec-
trophotometrically (Nitrate/Nitrite Colorimetric Assay Kit, Cayman
Chemical), following the manufacturer’s instructions. Plasma mel-
agatran concentrations were measured with liquid chromatography-
mass spectrometry (24).
Liver histology. Liver tissue sampled from each lobe was immer-
sion fixed in 4% formaldehyde in phosphate buffer (pH 7), stained
with hematoxylin and eosin and Masson trichrome, and processed for
analysis by light microscopy. Necrotic/apoptotic hepatocytes and
polymorphonuclear neutrophils (PMNs) were counted in 20 consec-
utive high-power fields (400). No distinction was made between cell
necrosis and apoptosis. Analyses were made by an investigator
blinded to treatment group.
Reverse transcription-polymerase chain reaction of liver tissue.
Liver tissue was snap frozen in liquid nitrogen and stored at 80°C
until analyzed. RNA was extracted with TRIzol reagent (Invitrogen,
Paisley, UK), and subsequently, cDNA was synthesized with the
Thermoscript reverse transcriptase-polymerase chain reaction (RT-
PCR) system (Invitrogen), following the manufacturer’s protocol.
Relative quantification of mRNA was performed on a LightCycler
(Roche) with SYBR Green I as described previously (14). Primer
sequences for TNF- (6), inducible nitric oxide synthase (iNOS) (35),
intercellular adhesion molecule (ICAM)-1 (6), and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (14) were obtained from the
literature and synthesized by Invitrogen. Amplification conditions for
TNF-, iNOS, ICAM-1, and GAPDH cDNA were as described in the
reference literature (6, 14, 35). Melting curve analysis was performed
to ensure single product amplification and verified by a single band on
an agarose gel. Relative expression of the target gene is shown as the
ratio between target and housekeeping gene (GAPDH) cDNA.
Kidney histology. Kidneys were decapsulated, weighed, and im-
mersion fixed in 4% formaldehyde in phosphate buffer (pH 7).
Kidneys were stained with hematoxylin and eosin and Masson
trichrome and processed for semiquantitative assessments by light
microscopy as previously described (12). The following variables
were quantified separately in the renal cortex, outer and inner
(ISOMZ) stripe of the outer medullary zone, and the inner medulla:
tubular atrophy and dilatation, PMN infiltration, interstitial edema,
interstitial inflammation and fibrosis, vascular fibrin deposition and
microthrombosis, and vascular congestion. Analyses were made by an
investigator blinded to treatment group using an arbitrary scale where
0 no changes, 1 mild focal changes, 2 modest diffuse changes,
and 3  severe diffuse changes, as described previously (12).
Statistics. Values are means SE except for semiquantitative data,
which are presented as medians with 25th and 75th percentiles.
Differences between groups were analyzed by one-way analysis of
variance (ANOVA) followed by Fisher’s post hoc test or ANOVA for
repeated measurements, when appropriate. The following prespecified
between-group analyses were performed: Sham-Saline vs. LPS-Saline
and LPS-Saline vs. LPS-Melagatran. Histological data were analyzed
by nonparametric Kruskal-Wallis and Mann-Whitney U-tests. A value
of P  0.05 was considered statistically significant. The statistical
software program SPSS 11.5.1 was used (SPSS, Chicago, IL).
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RESULTS
Systemic hemodynamics. Endotoxin administration caused a
significant 10% decrease in MAP (P  0.05; Fig. 1) and a
concomitant approximate 15% increase in HR (P 0.001; data
not shown). Melagatran had no significant effects on MAP
(Fig. 1) or HR in endotoxemic rats throughout the study period.
A transient increase in MAP (peak increase of 5%) was
observed in the Sham-Saline group (Fig. 1). There were no
significant differences in lung wet-to-dry weight ratio between
groups (data not shown). No significant hemorrhages and no
deaths occurred during experiments in any of the study groups.
Renal hemodynamics and function. At baseline, before LPS
administration, there were no statistically significant differ-
ences between groups in renal hemodynamics or function
except for an elevated rate of urinary potassium excretion
(UKV) in the LPS-Melagatran group (P  0.05; Table 1).
Endotoxin produced significant reductions in RBF, CLDF,
and GFR compared with sham-treated animals (P 0.05, Figs.
2 and 3). In addition, LPS decreased FF by 28  5% in the
LPS-Saline group (P  0.05 vs. sham treated). Endotoxin
caused a progressive decline in OMLDF over time compared
with sham-treated animals (group  time interaction P 
0.001, between groups P  0.07; Fig. 2). In the LPS-Saline
group, both absolute [data not shown for UNaV and UKV] and
FFH2O , FFNa, and FFK showed a significantly different pattern
Fig. 1. Effect of melagatran or isotonic saline on mean arterial pressure (MAP)
in thiobutabarbital-anesthetized rats infused with lipopolysaccharide (LPS).
LPS at a dose of 6 mg/kg was infused intravenously over 30 min from time 0
to 30 min (see MATERIALS AND METHODS). Values are means  SE. Statistical
analyses were performed by ANOVA for repeated measurements. ns, Not
statistically significant.
Fig. 2. Effect of melagatran or isotonic saline on renal blood flow (RBF; top)
and renal cortical (CLDF; middle) and outer medullary (OMLDF; bottom)
laser-Doppler fluxes in thiobutabarbital-anesthetized rats infused with LPS.
LPS at a dose of 6 mg/kg was infused intravenously over 30 min from time 0
to 30 min (see MATERIALS AND METHODS). Values are means  SE. Statistical
analyses were performed by ANOVA for repeated measurements. Group 
time, interaction between time and treatment group effects.
Table 1. Renal hemodynamics and function at baseline
Sham-Saline
(n  9)
LPS-Saline
(n  8)
LPS-Melagatran
(n  8)
BW, g 36911 32216* 32017*
MAP, mmHg 1163 1193 1242
HR, beats/min 3585 3668 3738
GFR, mlmin1g KW1 1.010.06 1.010.05 1.100.04
RBF, mlmin1g KW1 8.40.6 7.20.2 8.60.4
RVR, mmHg/
(mlmin1g KW1) 14.51.2 16.60.7 14.50.7
FF, % 12.40.8 14.00.7 12.90.8
CLDF, PU 67317 63128 67832
OMLDF, PU 1557 1367 15310
UV, lmin1g KW1 3.580.54 3.920.64 4.400.44
FENa, % 0.230.04 0.320.10 0.400.09
FEK, % 18.62.3 18.92.8 26.52.7
FEH2O, %) 0.370.07 0.380.06 0.400.04
UNaV, molmin1g KW1 0.220.05 0.260.10 0.410.08
UKV, molmin1g KW1 0.470.06 0.440.08 0.740.08*†
Values are means  SE of baseline renal clearance data in thiobutabarbital-
anesthetized rats presented as the average values of two 30-min clearance periods
before lipopolysaccharide (LPS) administration. BW, body weight; MAP, mean
arterial pressure; HR, heart rate; GFR, glomerular filtration rate; KW, kidney
weight; RBF, renal blood flow; RVR, renal vascular resistance; FF, filtration
fraction; CLDF, cortical laser-Doppler flux; PU, perfusion units; OMLDF, outer
medullary laser-Doppler flux; UV, urine flow rate; FENa, fractional urinary sodium
excretion; FEK, fractional urinary potassium excretion; FEH2O, fractional urine
flow rate; UNaV, urinary sodium excretion; UKV, urinary potassium excretion.
*P  0.05 vs. sham treated; †P  0.05 vs. LPS-Saline.
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over time compared with the Sham-Saline group (group time
interaction P  0.05; Fig. 4). Excretory responses in LPS-
treated animals were characterized by initial reductions fol-
lowed by pronounced increases starting at 90 min after
initiation of LPS infusion (Fig. 4).
Melagatran treatment significantly increased OMLDF in
LPS-injected animals (P  0.05, LPS-Melagatran vs. LPS-
Saline; Fig. 2). In addition, melagatran decreased UKV and
FEK (P  0.05; Fig. 4). However, there were no significant
differences between LPS groups in absolute levels of UKV and
FEK throughout the endotoxemic period (data not shown).
Melagatran had no statistically significant effects on RBF,
CLDF, GFR, FF, or absolute or fractional urinary excretion
rates of sodium or water, in endotoxemic rats (Figs. 2–4). In
the Sham-Saline group, RBF, CLDF, GFR, urine volume
(UV), FENa, and FEK increased significantly over time com-
pared with baseline values (P  0.05; Figs. 2–4).
Markers of liver injury. Administration of LPS caused sig-
nificant increases in AST, ALT, and bilirubin compared with
sham-treated animals (P  0.05; Fig. 5). Treatment with
melagatran significantly reduced the elevated plasma concen-
trations of AST (34  11%, P  0.05), ALT (21  7%,
P  0.05), and bilirubin (44  9%, P  0.05) in endotox-
emic rats (Fig. 5). LPS had no statistically significant effect on
plasma concentrations of pancreas-specific -amylase (data not
shown).
Effects of melagatran in sham-treated animals. Melagatran
had no statistically significant effects on RBF (	2  3% vs.
baseline), GFR (	4  2% vs. baseline), CLDF (	1  2% vs.
baseline), and OMLDF (	3  6% vs. baseline) in the Sham-
Melagatran group. Melagatran produced a modest reduction in
MAP evident after 3 h (6  1% vs. baseline, P  0.05).
Similar to the Sham-Saline group, UV, FENa, and FEK in-
creased significantly over time compared with baseline values
(P  0.05; data not shown). Plasma levels of AST, ALT, and
bilirubin were not significantly different from those in the
Sham-Saline group (data not shown). Plasma concentrations of
melagatran were 1.20  0.06 mol/l and not significantly
different from those in the LPS-Melagatran group.
Plasma TNF-, NO3/NO2, and melagatran concentrations.
Rats with endotoxemia demonstrated a marked, approximately
sevenfold increase in plasma TNF- concentrations (P 0.05;
Fig. 6). Melagatran treatment significantly decreased the ele-
vated plasma concentrations of TNF- by 32  14% (P 
0.05; Fig. 6). Endotoxin administration produced an 15-fold
increase in plasma NO3/NO2 compared with sham treatment
(P  0.05), with no significant difference between LPS-Saline
and LPS-Melagatran groups (Fig. 6). Plasma melagatran con-
centrations were 1.04  0.05 mol/l in the LPS-Melagatran
group when measured 4.5 h after the start of LPS administra-
tion.
Blood gases. Endotoxin produced an increase in plasma
lactate levels (P  0.05) and a decrease in PCO2 accompanied
by respiratory alkalosis (P  0.05; Table 2). There were no
significant differences in PO2 (Table 2), base excess, or plasmaFig. 3. Effect of melagatran or isotonic saline on glomerular filtration rate
(GFR) in thiobutabarbital-anesthetized rats infused with LPS. LPS at a dose of
6 mg/kg was infused intravenously over 30 min from time 0 to 30 min (see
MATERIALS AND METHODS). Values are means  SE. Statistical analyses were
performed by ANOVA for repeated measurements.
Fig. 4. Effect of melagatran or isotonic saline on urine volume (UV; top) and
fractional urinary sodium (FENa; middle) and potassium (FEK; bottom) excre-
tion in thiobutabarbital-anesthetized rats infused with LPS. LPS at a dose of 6
mg/kg was infused intravenously over 30 min from time 0 to 30 min (see
MATERIALS AND METHODS). Values are means  SE. Statistical analyses were
performed by ANOVA for repeated measurements.
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bicarbonate levels (data not shown) between study groups.
Both LPS-injected groups had significantly lower hemoglobin
concentrations compared with sham-treated animals (P 0.05;
Table 2).
Liver histology. Endotoxemia caused an 5-fold increase in
hepatocyte necrosis/apoptosis and a 25-fold increase in PMN
accumulation, predominantly in periportal areas, compared
with sham-treated animals (P  0.05; Fig. 7). There were no
apparent abnormalities in Kupffer cell morphology and no
increases in fibrin deposition, microthrombosis formation, or
sinusoidal congestion in endotoxemic rats (data not shown).
The LPS-Melagatran group had a similar degree of histopatho-
logical injury compared with the LPS-Saline group, and there
were no statistically significant differences in hepatocyte necrosis/
apoptosis or hepatic PMN sequestration between LPS-treated groups
(Fig. 7).
Hepatic gene expression of TNF-, iNOS, and ICAM-1.
Endotoxin administration significantly increased hepatic
mRNA levels of TNF-, iNOS, and ICAM-1 compared with
sham-treated animals (P  0.05; Fig. 8). Melagatran had no
statistically significant effects on TNF-, iNOS, or ICAM-1
gene expression (Fig. 8). There were no significant differences
between groups in the expression of the housekeeping gene
GAPDH (data not shown).
Kidney histology. There was no significant difference in
kidney weight between groups (data not shown). The LPS-
Saline group showed no statistically significant abnormalities
in any of the investigated renal histological variables compared
with sham-treated animals (data not shown). There was a
tendency toward an increased vascular congestion of erythro-
cytes in the ISOMZ in the LPS-Saline group compared with
sham-treated animals (P  0.24; data not shown). Melagatran
significantly decreased vascular congestion of erythrocytes in
the ISOMZ of LPS-injected animals [0 (0–0.25) vs. 1 (0–2) in
LPS-Melagatran and LPS-Saline groups, respectively, P 
0.05].
DISCUSSION
The main findings of the present study were that selective
thrombin inhibition with melagatran preserved renal outer
medullary perfusion, and reduced markers of liver injury and
plasma TNF- levels, during early endotoxemia in rats.
Fig. 5. Effect of melagatran or isotonic saline on plasma
concentrations of aspartate aminotransferase (AST; left), ala-
nine aminotransferase (ALT; center), and bilirubin (right) in
thiobutabarbital-anesthetized rats infused with LPS. Blood was
collected 4.5 h after start of LPS administration. Values are
means  SE. *P  0.05 vs. sham treated; †P  0.05 vs.
LPS-Saline.
Fig. 6. Effect of melagatran or isotonic saline on plasma
concentrations of tumor necrosis factor (TNF)- (left) and
nitrate (NO3)/nitrite (NO2) (right) in thiobutabarbital-anes-
thetized rats infused with LPS. Blood was collected 4.5 h
after start of LPS administration. Values are means  SE.
*P  0.05 vs. sham treated; †P  0.05 vs. LPS-Saline.
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In the present study, endotoxin caused an 50% decline in
GFR that was paralleled by significant reductions in RBF,
CLDF, and OMLDF. As the renal outer medulla is hypoxic
already during physiological conditions and therefore vulner-
able to reductions in blood flow (2), it is feasible to hypothesize
that the observed 20% decrease in OMLDF in endotoxemic
rats could have threatened outer medullary integrity. Although
melagatran did not improve GFR or attenuate tubular dysfunc-
tion during the first 3 h of endotoxemia, we speculate that
melagatran, by completely preventing the decrease in OMLDF,
could prevent ischemic tissue injury and improve kidney func-
tion long-term. However, this hypothesis needs to be addressed
in future studies by measuring outer medullary oxygen tension
in this model and by examining kidney function at later stages
of endotoxemia.
The mechanisms by which melagatran improved OMLDF
specifically during endotoxemia were not elucidated in the
present study. However, as melagatran did not have any sig-
nificant effects on MAP or total RBF in endotoxemic rats, our
results suggest that melagatran exclusively affected the renal
medullary microcirculation. Blood flow to the renal medulla is
regulated by a number of vasoactive substances that are syn-
thesized within the medulla and act through paracrine and
autocrine mechanisms (29). On the basis of anatomic consid-
erations, descending vasa recta seem to be an important site of
regulation of renal medullary blood flow. Descending vasa
recta are surrounded by contractile pericytes and respond to an
array of vasoactive agents in a manner similar to arterioles
(29). Interestingly, thrombin has been shown to cause renal
vasoconstriction through activation of PAR-1 (5, 11, 36). In a
recent study (28), it was demonstrated that melagatran inhib-
ited thrombin-induced PAR-1 cleavage in platelets in a dose-
dependent manner. Thus it is reasonable to speculate that
melagatran could inhibit thrombin-induced renal vasoconstric-
tion through inhibition of PAR-1 activation. However, to our
knowledge the effects of thrombin, and PAR activation, on
renal medullary microcirculation have not been examined.
Clearly, the mechanisms by which melagatran improved OM-
LDF in the present study need to be investigated further.
Interestingly, urinary sodium excretion increased markedly
90 min after LPS administration in endotoxemic rats, although
MAP, RBF, and GFR were reduced and the sympathetic
nervous system activated as indicated by pronounced eleva-
tions in HR. These endotoxin-induced abnormalities in tubular
function were not affected by melagatran treatment, although
melagatran improved OMLDF, indicating that tubular dysfunc-
tions were not caused by outer medullary ischemia. In the
present study there was a transient, modest rise in MAP and
progressive increases in RBF, GFR, UV, FENa, and FEK, over
time in the Sham-Saline group. These findings could probably
be explained by extracellular fluid volume expansion, as ani-
mals were resuscitated with intravenous saline to resemble the
clinical situation in septic patients. Indeed, when comparing
infused volume to urine output for each clearance period, all
study groups were in clear positive fluid balance throughout.
It may be argued that the modest effect of melagatran on
kidney function in the present study could be explained by low
rates of thrombin generation during early endotoxemia. How-
ever, it was previously shown that the coagulation system is
markedly activated, and thrombin generation increased, al-
ready during the first hours after endotoxin administration (3,
31). Furthermore, since thrombin has a high affinity for PAR-1
(4, 28), increased thrombin generation would most likely also
result in PAR-1 activation. In addition, the dose of melagatran
in the present study was appropriate since plasma melagatran
concentrations of 1 mol/l have been shown to exert almost
complete thrombin inhibition and pronounced antithrombotic
effects in vivo (8) and to inhibit thrombin’s activation of
PAR-1 and -4 in vitro (28).
Activated coagulation factors have been implicated in the
pathogenesis of liver injury in endotoxemia (26). Corroborat-
Table 2. Arterial blood gases
Sham-Saline
(n  11)
LPS-Saline
(n  12)
LPS-Melagatran
(n  12)
Hb, g/l 1342 1172* 1126*
Lactate, mmol/l 0.730.04 1.770.18* 1.670.11*
pH 7.420.01 7.510.01* 7.500.01*
PCO2, kPa 4.750.14 3.650.18* 3.660.13*
PO2, kPa 10.510.32 11.560.35 10.900.28
Values are means  SE for arterial blood gases in thiobutabarbital-anes-
thetized rats 4.5 h after start of LPS infusion. Hb, hemoglobin; PCO2, partial
pressure of carbon dioxide; PO2, partial pressure of oxygen. *P  0.05 vs.
sham treated.
Fig. 7. Effect of melagatran or isotonic saline on hepatocyte
necrosis/apoptosis (left) and hepatic polymorphonuclear neu-
trophil (PMN) infiltration (right) in thiobutabarbital-anesthe-
tized rats infused with LPS. Liver tissue was sampled 4.5 h
after start of LPS administration. Necrotic/apoptotic hepato-
cytes and PMN were counted in 20 consecutive high-power
fields (HPF) at 400 magnification. Values are means  SE.
*P  0.05 vs. sham treated.
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ing these findings, thrombin inhibition with melagatran de-
creased plasma AST, ALT, and bilirubin levels by 20–45% in
endotoxemic animals, although we could not detect beneficial
effects on liver morphology. Presumably, we would have been
able to detect less severe hepatocellular injury in melagatran-
treated rats with more sensitive histological methods, e.g.,
electron microscopy. It is well established that impaired hep-
atocellular integrity, and not necessarily cell death, can cause
release of aminotransferases into the circulation. Thus it is
feasible to hypothesize that the positive effects of melagatran
on liver function tests reflected less severe hepatocellular
injury. Furthermore, beneficial effects of melagatran on liver
integrity might have been detected earlier with liver function
tests than by histological analyses. This is supported by obser-
vations in other models of hepatic injury in rats (23).
In the present study melagatran did not decrease PMN
accumulation in the liver, or the hepatic gene expression of
TNF-, ICAM-1, or iNOS, in endotoxemic rats. In addition,
LPS-injected animals showed no apparent hepatic microthrom-
bosis. Therefore, and as suggested by others (3, 26), our data
imply that thrombin inhibition does not attenuate liver dys-
function in endotoxemia by decreasing PMN accumulation or
by reducing microthrombosis formation. We speculate that
melagatran could have attenuated liver dysfunction in the
present study by inhibiting PAR-1 activation and/or by pre-
serving liver blood flow. In this regard, Copple et al. (3) have
shown that PAR-1 activation by thrombin causes hepatic injury
after LPS infusion. In addition, decreased liver blood flow has
been demonstrated in a similar model of endotoxemia in rats
(38). Furthermore, the thrombin inhibitors heparin and anti-
thrombin have been shown to improve microvascular perfusion
in the splanchnic circulation during endotoxemia (21). Thus
melagatran might have had positive effects on liver blood flow,
similar to that in the renal outer medulla, in the present study.
Additional studies are required to determine how melagatran
reduced liver dysfunction during early endotoxemia.
Finally, melagatran treatment reduced plasma TNF- con-
centrations by30% in endotoxemic rats. TNF- is a cytokine
known to propagate inflammation and organ damage in sepsis
(15). Furthermore, plasma TNF- levels correlate with mor-
tality in septic patients (15). Knotek et al. (22) found that
TNF- neutralization ameliorated early renal dysfunction in
endotoxemic mice. Similarly, pretreatment of rats with TNF-
antiserum afforded protection against liver injury early after
LPS exposure (16). Thus it is reasonable to speculate that
melagatran may have beneficial effects in endotoxemia through
its effect on plasma TNF- levels. Interestingly, although
melagatran reduced plasma TNF- levels, hepatic gene expres-
sion of TNF- was unaffected. This finding could be explained
by the fact that monocytes are a major source of plasma TNF-
in endotoxemia (1). In support of this hypothesis, it has been
demonstrated that thrombin increases the secretion of TNF-
from monocytes exposed to endotoxin (18), and that thrombin
inhibition decreases TNF- production in these cells (17).
Recent studies suggest that activation of the coagulation sys-
tem enhances systemic inflammation in endotoxemia, although
the coagulation factors participating in the proinflammatory
response have not been defined (30, 31). Our results clearly
indicate a role for thrombin-dependent signaling in this pro-
cess.
In conclusion, thrombin inhibition with melagatran pre-
served renal outer medullary perfusion, ameliorated liver dys-
function, and reduced plasma TNF- levels in endotoxemic
rats. These findings may have important implications, as they
suggest protective effects of thrombin inhibition in sepsis, a
clinical condition associated with a bad prognosis.
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Fig. 8. Effect of melagatran or isotonic saline on hepatic gene expression of
TNF- (top), inducible nitric oxide synthase (iNOS; middle), and intercellular
adhesion molecule (ICAM)-1 (bottom), relative to the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in thiobutabarbital-
anesthetized rats infused with LPS. Liver tissue was sampled 4.5 h after start
of LPS administration. Analyses were performed by reverse transcription-
polymerase chain reaction. Values are means  SE. *P  0.05 vs. sham
treated.
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